You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,985,559


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,985,559
Title:Methods of selecting epidermal growth factor receptor (EGFR) binding agents
Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
Inventor(s): Freeman; Daniel J. (Newbury Park, CA), Sun; Jilin (Thousand Oaks, CA), Jung; Kenneth H. (Newbury Park, CA), Elliott; Gary S. (Thousand Oaks, CA), Radinsky; Robert (Thousand Oaks, CA)
Assignee: AMGEN Inc. (Thousand Oaks, CA)
Application Number:12/288,341
Patent Claims:1. A method of selecting a specific binding agent to an epidermal growth factor receptor (EGFr) polypeptide, wherein the specific binding agent binds to at least a portion of a panitumumab epitope on an EGFr polypeptide, comprising: a) contacting an EGFr polypeptide with an agent, wherein the EGFr polypeptide comprises the L2 domain of EGFr set forth in SEQ ID NO:3; b) determining the affinity of the agent for the EGFr polypeptide; c) contacting a mutant EGFr polypeptide with the agent, wherein the mutant EGFr polypeptide comprises at least one point mutation in at least one amino acid position selected from P349A, D355T, F412A, I438A, K443A, K465A, and I467A; d) determining the affinity of the agent for the mutant EGFr polypeptide; and e) selecting the agent if the affinity for the EGFr polypeptide is at least 2-fold greater than the affinity for the mutant EGFr polypeptide.

2. The method of claim 1, wherein the mutant EGFr polypeptide is the same as the EGFr polypeptide except for the at least one mutation.

3. The method of claim 1, wherein the agent is selected from a protein, peptide, nucleic acid, carbohydrate, lipid, and small molecule compound.

4. The method of claim 3, wherein the agent is an antibody.

5. The method of claim 3, wherein the agent is a small molecule compound.

6. The method of claim 1, wherein the affinity for the EGFr polypeptide is at least 5-fold greater than the affinity for the mutant EGFr polypeptide.

7. The method of claim 1, wherein the affinity for the EGFr polypeptide is at least 10-fold greater than the affinity for the mutant EGFr polypeptide.

8. A method of selecting a specific binding agent to an epidermal growth factor receptor (EGFr) polypeptide, wherein the specific binding agent does not bind to a panitumumab epitope on an EGFr polypeptide (EGFr), comprising: a) contacting an EGFr polypeptide with an agent, wherein the EGFr polypeptide comprises the L2 domain of EGFr set forth in SEQ ID NO:3; b) determining the affinity of the agent for the EGFr polypeptide; c) contacting a mutant EGFr polypeptide with the agent, wherein the mutant EGFr polypeptide comprises at least one point mutation in at least one amino acid position selected from P349A, D355T, F412A, I438A, K443A, K465A, and I467A; d) determining the affinity of the agent for the mutant EGFr polypeptide; and e) selecting the agent if the affinity for the EGFr polypeptide is similar to the affinity for the mutant EGFr polypeptide.

9. The method of claim 8, wherein the mutant EGFr polypeptide is the same as the EGFr polypeptide except for the at least one mutation.

10. The method of claim 8, wherein the agent is selected from a protein, peptide, nucleic acid, carbohydrate, lipid, and small molecule compound.

11. The method of claim 10, wherein the agent is an antibody.

12. The method of claim 10, wherein the agent is a small molecule compound.

13. The method of claim 8, wherein there is less than a 2-fold difference between the affinity for the EGFr polypeptide and the affinity for the mutant EGFr polypeptide.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.